Skip to main content

Table 3 Factors associated with virological non-suppression among HIV patients on ART, August 2014–July 2015, (N = 100,678)

From: Factors Associated with Virological Non-suppression among HIV-Positive Patients on Antiretroviral Therapy in Uganda, August 2014–July 2015

Variable

Not suppressed (%)

Suppressed (%)

ORcrude(95%CI)

ORadj(95%CI)a

Reason for testing

 Routine testing

8966(84)

8966(96)

1.0

1.0

 Suspected treatment failure

1018(10)

2474(3.0)

4.2(3.6–4.2)

3.3(3.0–3.6)

 Repeat testers after suspected failure

716(6)

720(1.0)

9.5(8.6–10)

6.3(5.5–7.2)

Age category

 35+

4119(38)

52,527(59)

1.0

1.0

 34–30

1579(15)

13,915(16)

1.4(1.4–1.5)

1.6(1.5–1.7)

 29–25

1141(11)

9554(11)

1.5(1.4–1.6)

1.9(1.7–2.0)

 24–20

746(7)

4035(5)

2.4(2.2–2.6)

2.7(2.5–3.0)

 19–15

837(8)

2248(3)

4.7(4.4–5.2)

4.1(3.7–4.6)

 14–10

960(9)

3271(4)

3.7(3.5–4.1)

3.3(2.9–3.7)

 9–5

916(9)

3067(3)

3.8(3.5–4.1)

3.4(3.1–3.8)

 4–0

507(5)

1256(1)

5.1(4.6–5.7)

5.3(4.6–6.1)

Indication for treatment initiation

 PMTCT/Option B+

589(6)

9231(11)

1.0

1.0

 Child <15 Years

1826(19)

5886(7)

4.9(4.4–5.6)

2.1(1.9–2.4)

 TB infection

194(2)

1302(2)

2.3(1.9–2.8)

2.1(1.8–2.6)

 CD4 < 500

7169(73)

67,232(80)

1.7(1.5–1.8)

2.0(1.8–2.2)

ARV adherence

  > 95%

8145(79)

77,295(89)

1.0

1.0

 85–94%

1659(17)

8406(8)

1.9(1.8–2.0)

1.6(1.5–1.7)

  < 85%

453(4)

839(1)

5.1(4.6–5.8)

3.4(2.9–3.9)

Treatment line

 First line

9945(93)

8453(95)

1.0

1.0

 Second/Third line

747(7)

4800(5)

1.3(1.3–1.4)

0.86(0.78–0.95)

Sex

 Female

6524(61)

60,573(68)

1.0

1.0

 Male

4132(39)

28,071(32)

1.4(1.3–1.4)

1.2(1.1–1.3)

Active TB

 No

1,0236(99)

86,650(99)

1.0

1.0

 Yes

131(1)

537(1)

2.1(1.7–2.5)

1.9(1.6–2.4)

Health Facility Level

 HCII + HCIII

1455(13)

13,949(16)

1.0

1.0

 HCIV + General hospital

2293(21)

23,809(27)

0.92(0.86–0.99)

0.89(0.82–0.97)

 Specialized HIV services

1482(14)

12,462(14)

1.1(1.1–1.2)

1.2(1.1–1.3)

 RRH + NRH

5575(52)

39,628(44)

1.3(1.3–1.4)

1.0(0.96–1.1)

Duration on treatment

 0–2 Years

3680(34)

32,661(36)

1.0

1.0

 3–5 Years

3900(36)

29,028(32)

1.2(1.1–1.3)

1.3(1.2–1.4)

 6–10 Years

2928(27)

2549(28)

1.0(0.97–1.1)

1.1(1.1–1.2)

  > 10 Years

257(3)

2469(4)

0.92(0.81–1.1)

0.91(0.78–1.1)

Breast feeding

 No

5964(95)

54,369(93)

1.0

 

 Yes

297(5)

4400(8)

0.61(0.54–0.69)

Pregnant

 No

6113(98)

56,841(97)

  

 Yes

153(2)

1856(3)

0.77(0.65–0.91)

  1. Denominator for pregnant/breastfeeding mothers was total females in the sample
  2. HCII health centre two, HCIII health centre three, HCIV health centre four, RRH regional referral hospitals, NRH national referral hospitals
  3. aWe adjusted for age, sex, ARV adherence, treatment line (first, second/third), identification for treatment initiation at baseline (ePMTCT option B+, child under 15, CD4 < 500 and TB infection), having active TB, duration on treatment, and health facility level